University of Queensland
Brisbane, Queensland, 4072, Australia
NCT Number: NCT00381082
Objective
To compare the cure rates (defined as the complete absence of live lice, adults or nymphs, as diagnosed by wet-combing of three Australian approved head lice products for the treatment of primary school children with head lice infestation. The study design will be randomised and assessor-blind using three comparative parallel treatment groups.
The study population will consist of Queensland state primary school children (up to Year 7) with live head lice (adults or nymphs) on the hair or scalp who have not used any head lice product in the four weeks prior to the study.
Looking for future studies?
Notify Me5 year–12 year
All sexes
Interventional
Phase 2 / Phase 3
Brisbane, Queensland, 4072, Australia
All products were used according to the manufacturer's instructions. KP24 and Banlice were applied twice separated by a one week interval. MOOV Head Lice Treatment was applied on Day 0, Day 7 and Day 14. The cure rate (absence of live lice) one day after the first administration for all products was a secondary outcome measure. The cure rate at 7 days after the final administration (Day 14 for Banlice or KP24 and at Day 21 for MOOV Head Lice Treatment) was the primary outcome measure. Siblings were treated if these were found to be infected as an enrolment criteria.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Uniquest Pty Ltd
Other
A Randomised, Controlled and Blinded Assessment Study of the Efficacy of MOOV Head Lice Treatment (Ego Pharmaceutical Pty. Ltd.) in the Treatment of Head Lice in Primary School Children.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05643820
Ectoparasitic Infestations, Infections
Abbottabad, KPK, Pakistan
View Trial DetailsNCT01518699
Ectoparasitic Infestations, Infections
West Bend, Wisconsin, United States
View Trial DetailsNCT01336647
Ectoparasitic Infestations, Infections
Dinuba, California, United States
View Trial DetailsNCT00752973
Ectoparasitic Infestations, Infections
Bentonville, Arkansas, United States
View Trial Details